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Summary
BACKGROUND: Infantile haemangiomas (IHs) are very
common vascular tumours. Propranolol is at present the
first-line treatment for problematic and complicated hae-
mangioma. In accordance with a Swiss protocol, children
are monitored for 2 days at the start of the treatment to de-
tect possible side effects of this drug. Our study advocates
a simplification of the pretreatment monitoring process.
METHODS: All children with a problematic and com-
plicated haemangioma treated with propranolol between
September 2009 and September 2012 were included in the
study. All patients were hospitalised under constant nurse
supervision for 48 hours at the start of the treatment and
subjected to cardiac and blood measurements. The dosage
of propranolol was 1 mg/kg/day on the first day and 2 mg/
kg/day from the second day. Demographic data, clinical
features, treatment outcome and complications were ana-
lysed.
RESULTS: Twenty-nine infants were included in our study.
Of these, 86.2% responded immediately to the treatment.
There were no severe adverse reactions. Six patients
presented transient side effects such as bradycardia, hypo-
tension after the first dose and hypoglycaemia later. No
side effects occurred after the second dose. Treatment was
never interrupted.
CONCLUSION: Propranolol (a β-blocker) is a safe treat-
ment for problematic IH. Side effects may occur after the
first dose. A strict 48 hour monitoring in hospital is expens-
ive and may be unnecessary as long as the contraindica-
tions for the drug are respected.
Key words: infantile haemangioma; propranolol; vascular
tumour
Background
Infantile haemangiomas (IHs) are present in 10% of chil-
dren under the age of 1 year, and are the most common be-
nign tumours of infancy [1]. An especially high incidence
of haemangioma has been reported in very premature ba-
bies [2, 3]. Eighty percent are solitary lesions. Sixty percent
are located in the cervicofacial region, the others arising
on the trunk and the extremities. Multiple haemangiomas
(more than five) are known to be associated with visceral
lesions, most often hepatic and gastrointestinal [4].
Haemangiomas are proliferative vascular lesions due to an
accelerated turnover of endothelial cells. Their appearance
within a few weeks after birth is followed by a period of
rapid growth during early infancy. The maximum peak of
activity occurs between 5 and 6 months of age, and its max-
imum duration is 1 year [5]. This phase is followed by a
stable period of a few months and then a spontaneous in-
volution over several years. During the involution phase,
the turgescence of the tumour will decrease and the colour
will change from purple-red to grey. The involution may
be complete or partial, and the residual skin may be re-
dundant, atrophic and telangiectatic. If spontaneous invol-
ution is very rapid, bleeding and ulceration of the tumour
may call for surgical excision or laser treatment. Congenit-
al haemangiomas, distinct from the haemangiomas that ap-
pear after birth, are tumours which are fully developed at
birth, do not have a proliferation phase and regress a few
months after birth [3].
As a result of variations in their size, shape and behaviour,
infantile haemangioma present a broad spectrum of clinical
features and vary greatly in their response to treatment. The
choice of treatment of the lesions is determined by their
location and rate of growth. Facial, anal, vulvar or mam-
mary haemangiomas may give rise to functional impair-
ment or ulceration [1, 2]. Periorbital haemangiomas may
cause visual impairment with amblyopia or anisometropia.
Heavy facial haemangiomas may cause lip or eyelid de-
formation with ectropion. Parotid gland haemangiomas
may cause obstruction of the external auditory canal. Anal
and vulvar haemangiomas may develop ulceration by irrit-
ation. Subglottic lesions may cause stridor and life-threat-
ening airway obstruction. The clinical heterogeneity of
these lesions challenges care providers, who have to distin-
guish among the range of lesions that must be treated rap-
idly and carefully during early infancy.
Our approach to the treatment of subglottic or infiltrative
haemangiomas has been totally modified in view of the
remarkable effectiveness of oral propranolol (a β-blocker)
[6–8]. Its possible side effects are bradycardia, hypotension
and impaired response to hypoglycaemia [9, 10]. The treat-
ment starts with 1 mg/kg/day orally on the first day, raised
to 2 mg/kg/day from the second day on. The ideal duration
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of treatment and the risk of reappearance of the lesions at
the end of the treatment are still subjects of debate [11, 12].
Whereas the efficacy of the treatment with propranolol in
stopping the development of proliferative haemangioma is
generally recognised, the initial monitoring of the treatment
is still a matter of debate. The custom in our country is to
hospitalise the children for 48 hours for preliminary blood
glucose measurement and cardiac ultrasound investigation,
and for monitoring of vital signs at the start of the treatment
[13]. The purpose of this study is to point out that the low
frequency and severity of drug-related side effects during
the initial phase of treatment may justify a simplification of
the 48-hour monitoring in a hospital setting.
Methods
In this retrospective study, we reviewed data from all chil-
dren with a problematic and complicated haemangioma
treated with propranolol between September 2009 and
September 2012 in the Paediatric Surgery Department of
the University Hospital in Lausanne (CHUV). All the chil-
dren were treated in accordance with the Swiss protocol es-
tablished by the Swiss Grand Round for Vascular Anom-
alies in Childhood [10, 13]. This protocol established the
indications for using propranolol in the treatment of prob-
lematic haemangiomas (voluminous, multiple, ulcerated)
and complicated haemangiomas (face, orifices, extremities,
genital or subglottic). Before the initiation of propranolol
treatment, blood glucose levels and renal function were
first checked, and a cardiac ultrasound and electrocardio-
gram (ECG) were performed by paediatric cardiologists.
Then, when all results were normal, and the parent’s con-
sent obtained, patients were hospitalised in our department
for continuous monitoring during 48 hours at the start of
the treatment. Blood pressure and cardiac rhythm were
checked every 30 minutes for 4 hours after the treatment.
The treatment with propranolol was initiated with 1 mg/
kg/day in the first 24 hours and then 2 mg/kg/day from
the second day onwards if the first dose was well tolerated
[10, 13]. The dosage was not adapted according to body-
weight from 11 months to the first birthday. Treatment with
2 mg/kg/day propranolol was generally maintained during
the first year of life (or longer in the case of recurrence).
Heart malformations, respiratory problems such as bron-
chiolitis or asthma were contraindications to commencing
treatment.
For ulcerated haemangiomas, alginate or hydrocolloids
dressings with eosin® 2% was used for local treatment
in addition to propranolol. After 48 hours, the treatment
was continued on an outpatient basis, with oral propranolol
2 mg/kg/day given in three doses. Parents were advised
to temporarily discontinue the treatment if problems oc-
curred, especially in cases of bronchiolitis or respiratory
problems. Follow-up was organised in our clinic after 1
week and again after 4 weeks and then every 8 weeks. Par-
ents were invited to call in the event of recurrence of the
haemangioma. Clinical condition, weight, heart rate and
blood pressure were recorded at each visit and dosage of
propranolol adapted according to bodyweight. Character-
istics of the haemangioma, such as colour, size and consist-
ency were evaluated. Photographs were taken as an object-
ive tool of comparison. Possible treatment complications
were noted.
Treatment evaluation, based on clinical examination and
photographs, was performed by the same team of surgeons
experienced in treating haemangiomas and vascular mal-
formations. Epidemiological data, IH clinical features,
treatment outcome and complications were collected from
medical files.
Response to propranolol was categorised as excellent,
moderate or absent. Excellent response was defined as a
rapid initial discoloration and noticeable decrease in the
size of the tumour. Clinical response was considered good
when spontaneous ocular opening and healing of ulceration
with relief from pain were observed. The response was
qualified as moderate when improvement was less obvi-
ously present.
Results
Twenty-nine patients were treated with propranolol
between September 2009 and September 2012. There was a
predominance of female patients (21/8). Five patients were
preterm.
Twenty patients (67%) had a solitary haemangioma and
nine had multiple ones. Haemangioma were located re-
spectively on the face (fig. 1), on the trunk, on the extremit-
ies, in the subglottic areas, and in the genital areas (table 1
and fig. 2). Twenty-two children had a cutaneous tumour,
nine had a subcutaneous tumour and seven deep haeman-
gioma. Deep ulceration was observed in four children on
their first clinical examination. Prior to the initiation of pro-
Figure 1
Infantile haemangioma of the face at 2 months (left) and after 2
weeks (right) of treatment with propranolol (2 mg/kg/day).
Figure 2
Two examples of genital area haemangiomas complicated by
ulceration. Left: before treatment. Right: after treatment with
propranolol (2 mg/kg/day).
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pranolol treatment, all cardiac ultrasound and ECGs per-
formed by paediatric cardiologists were normal, and all
children could start the treatment. None of the children had
respiratory problems, with bronchiolitis or asthma postpon-
ing the treatment. Blood glucose levels and renal function
were all normal and consent was obtained from all parents
after our explanation.
Eleven patients underwent diagnostic imaging or endo-
scopic studies: three endoscopies for respiratory tract ob-
struction, three magnetic resonance imaging (MRI) exam-
inations for subcutaneous orbital tumours, three ultrasound
examinations for parotid mass, and two abdominal ultra-
sound examinations because of multiple cutaneous hae-
mangiomas (>5) without an associated visceral tumour.
Clinical examination alone was sufficient to reach a dia-
gnosis in the remaining cases. Four patients (13.8%) had
previously received treatment for their haemangioma: two
were already being treated with a corticosteroid, without
any positive response, and three had been treated with
pulsed-dye laser.
The median age at the start of propranolol treatment was
3.5 months, ranging from 1.5 to 12 months. Propranolol
was started at 1mg/kg/day in all patients. The initial re-
sponse to the drug was excellent in 25 out of 29 children
(86.2%) and moderate in four.
The median duration of the treatment was 7.1 months
(range: 4 to 16 months) for 28 children. One patient, who
is now 3 years old, is still under treatment because of the
immediate recurrence of the haemangioma when we tried
to stop the treatment. Three patients were still being treated
after 1 year of age because we observed a rebound of
the lesions when the treatment was stopped. The treatment
was continued after their first birthday for 3 (twice) and 4
months. No late recurrence of a haemangioma was noted in
our study.
None of our patients showed severe side effects at the be-
ginning or during the treatment. We did, however, have
four mild cases of transient decreased blood pressure (a de-
crease of more than 15% of mean arterial pressure): the
children’s ages were 7 months and 20 days, 7 months and
10 days, 9 months and 6 days, and 11 months (table 2).
These children were not the youngest among our popula-
tion. For two of them, we remained at a dosage of 1mg/
kg/day because even with this lower dosage, the effective-
ness on the haemangioma was excellent. Two other chil-
dren presented a lower heart rate after the first dose of
the drug. No other clinical symptoms were noticed and the
dose was increased to 2 mg/kg/day. One child had late hy-
poglycaemia at 7 months after 3 months of treatment.
Discussion
As haemangiomas will spontaneously decrease after a few
years, treatment during the proliferation phase is reserved
for functional or psychological problems, or bleeding and
ulceration of the tumour if spontaneous involution is very
rapid. Depending on the rhythm of proliferation, ulceration
and bleeding, as well as congestive heart failure, may oc-
cur. However, there are no indicators to predict the eventual
volume of a particular haemangioma or forecast the timing
and outcome of evolution or involution.
During the proliferation phase, the endothelial cells are
tightly packed sinusoidal channels with multilaminated
basement membrane and numerous cellular mitoses [14].
During the involution phase, the lesion presents a decrease
of endothelial proliferation, a decrease in cellularity and
size, large vascular channels, apoptosis and fat prolifera-
tion with fibrous septa and softness of the overlying skin.
The type of involution cannot be predicted; it may be com-
plete or partial, and the residual skin could be redundant,
atrophic and telangiectatic.
Oral steroids are, if possible, no longer given, because of
side effects such as Cushing’s syndrome, with growth re-
tardation, hirsutism, arterial hypertension, immunosuppres-
sion and increased risks of infection [5]. Interferon ther-
apy for subglottic haemangiomas induces the involution
of the tumour through endothelial cell apoptosis, but also
causes side effects such as malaise, spastic diplegia, neut-
ropenia and liver enzymes increases [16]. Carbon diox-
ide laser ablation, also used for subglottic haemangiomas,
induces scarring and laryngeal stenosis, which could re-
quire a tracheostomy. Direct injection of steroids (beta-
methasone) requires general anaesthesia and has been as-
sociated with necrosis, skin atrophy or globe penetration.
Chemotherapy and radiation have side effects such as peri-
Table 1: Location of 40 haemangiomas in 29 children.
Number %
Face 21 52
Trunk 6 15
Extremities 7 18
Subglottic area 3 7.5
Genital area 3 7.5
Table 2: Summary of the adverse effects of propranolol treatment.
WhenPatient Gender Age at the beginning
of treatment
Adverse effect
Early Late
Location of tumour
8 F 4 mo 21 d Bradycardia First dose Subglottic
11 F 7 mo 20 d Hypotension First dose Face
15 F 7 mo 10 d Hypotension
Hypoglycaemia
First dose 3 mo of treatment Face
16 M 9 mo 6 d Hypotension First dose Face
21 M 11 mo Hypotension First dose Face
25 F 7 mo 10 d Bradycardia First dose Face
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pheral neuropathy and bone growth delay, and are no
longer used [15].
Surgical excision under general anaesthesia may be pre-
ferred if the lesion does not respond to medical treatment
or if it bleeds, but this carries the risk of a disfiguring
scar. When the lesion is flat, flash lamp-pumped pulsed-
dye therapy (laser) is very effective in arresting the prolif-
eration phase by closing the vessels and reducing the blood
supply to the lesion. This procedure should be repeated
after 1 month for it to be completely effective. It does not
necessarily require anaesthesia, but perfect eye protection
is mandatory.
The use of oral propranolol (a β-blocker) is a very effective,
fast and revolutionary treatment, which has completely
changed our attitude towards subglottic, infiltrative and ul-
cerative haemangiomas [7, 17]. Previously, the use of pro-
pranolol for the treatment of heart problems and increased
arterial pressure was widely accepted. Now its use in the
treatment of haemangiomas is also widely accepted since
many publications have showed its efficacy, especially for
subglottic haemangiomas, for which other treatments were
disappointing with severe side effects. The fact that the en-
dothelial cells of a haemangioma express receptors to β-
blockers leads us to suspect that the mechanism of effic-
acy of this treatment is a decreased production of vascular
endothelial growth factor (VEGF) and fibroblast growth
factor-β (FGF-β). The therapeutic effect of propranolol in-
cludes vasoconstriction, inhibition of angiogenesis and in-
duction of apoptosis in capillary endothelial cells [17, 18].
As previously reported, the most common dosage of pro-
pranolol was 2 mg/kg/day. This has proved to be safe and
effective, with very few side effects [12]. Other papers ad-
vocate a daily dosage of 1 to 3 mg/kg/day, administered in
three doses. A progressive dosage is usually recommended
at the beginning of the treatment [10]. In our study, daily
doses of 2 mg/kg were given orally to all patients during
the proliferation phase. Two of our children were kept on a
dosage of 1 mg/kg/day because of hypotension at this dose,
but even on this lower dosage, the effectiveness on the hae-
mangioma was already obvious after the second day. In our
study, we wanted to keep the same dosage and same pro-
tocol for all children in order to diminish bias. However, for
these two children, the decrease of blood pressure and the
fast and excellent response at the initiation of the treatment
convinced us not to increase the dosage to 2 mg/kg/day. We
are under the impression that 1 mg/kg/day of propranolol
is sufficient to treat haemangioma but to prove it we would
need to create two groups of children in a randomised study
with two different doses per kilogram in order to determine
if the response to the propranolol treatment is dosage de-
pendant or not.
The side effects of β-blocker treatment reported in the lit-
erature are asymptomatic hypotension, bradycardia, bron-
chospasm, hypoglycaemia and hyperkalaemia. It is there-
fore recommended that very young babies undergoing this
treatment be hospitalised and subjected to blood glucose
checks, cardiac ultrasound investigations and monitoring
of vital signs (cardiac frequency and arterial pressure). Oth-
er complications such as insomnia, somnolence, cool or
mottled extremities, diarrhoea and hair loss are less fre-
quent and less dangerous [13]. An increasing number of
publications confirm the absence of adverse effects, even
in low birth weight newborns. Of the 85 articles presented
at an American conference in Chicago in 2011, 48 reported
no complications in any patient [10]. Treatment of outpa-
tients with monitoring seems to be possible for children
older than 8 weeks. Hospitalisation is suggested for infants
of less than 8 weeks or for children with comorbid con-
ditions affecting the cardiovascular or respiratory system
[10]. At the same conference, it was stipulated that echo-
cardiography as a routine screening tool is not necessary
in the absence of abnormal clinical findings. Pretherapeutic
assessment, including ECG, echocardiography and blood
examinations, seems to be necessary only in some cases,
such as known bradycardia, a family history of congenital
heart conditions or arrhythmias. Betlloch-Mas et al. recom-
mend that children be checked 5 hours after receiving the
first dose [19]. A 48-hour hospitalisation for the initiation
of propanolol therapy is nevertheless very expensive (from
2160 to 2540 CHF [2800–3200 €]).
According to our Swiss protocol, treatment was started at
the hospital with continuous observation by nurses during
48 hours, irrespective of the age of the child [11]. Median
age at the initiation of the therapy was 3.5 months. In three
cases, we started the treatment after the end of the "theoret-
ical" proliferative phase (9, 11 and 12 months of age). The
results of this treatment were excellent in two cases and
moderate in the third case. There is still no evidence con-
cerning the optimal length of treatment in these exceptional
cases [18].
All patients were assessed before treatment was initiated.
Follow-up consisted in routine assessments by both our
team and by the patient's own paediatrician to determine
any necessary dosage adjustments. We adapted the dosage
per kilogram up until 10 months of age, then gave half
the dosage at 11 months and stopped the treatment at 12
months, in spite of the lack of evidence concerning the be-
nefit of a progressive dosage decrease [20, 21]. The great
majority of infants treated for IH in our study did not
present any side effects. No insomnia, somnolence, cool or
mottled extremities, diarrhoea or hair loss occurred. The
transient hypotension and bradycardia seen in six of our pa-
tients (table 2) did not prevent the continuation of the treat-
ment at a dosage of 2 mg/kg/day, except for two babies who
were kept on a dosage of 1 mg/kg/day. Only one of our pa-
tients developed hypoglycaemia. We find that giving pro-
pranolol with meals is an effective precaution for avoiding
this particular side effect.
Conclusions
This study shows that although side effect reactions may
occur after the first dose of the drug, they are not severe.
Nevertheless, we had two children with a lower heart rate
after the first dose of the drug and four children with a
transient decrease of blood pressure (15% of mean arterial
pressure), for two of whom we kept the dosage of 1 mg/
kg/day as the effectiveness on the haemangioma was ex-
cellent. In view of these results, there will be a discussion
in our "National Grand Round for Vascular Anomalies in
Childhood". The 48-hour hospitalisation for the initiation
of propanolol therapy seems to be not necessary as long as
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contraindications to the drug and strict monitoring after the
first dose are adhered to.
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Figures (large format)
Figure 1
Infantile haemangioma of the face at 2 months (left) and after 2 weeks (right) of treatment with propranolol (2 mg/kg/day).
Figure 2
Two examples of genital area haemangiomas complicated by ulceration. Left: before treatment. Right: after treatment with propranolol (2 mg/kg/
day).
Original article Swiss Med Wkly. 2014;144:w13943
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 6 of 6
